Cargando…
The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study
BACKGROUND: There is no standard neoadjuvant therapy for locally advanced esophageal cancer in China. The role of neoadjuvant chemotherapy plus immunotherapy for locally advanced esophageal cancer is still being explored. METHODS: This open-label, randomized phase II study was conducted at a single...
Autores principales: | Xing, Wenqun, Zhao, Lingdi, Zheng, Yan, Liu, Baoxing, Liu, Xianben, Li, Tiepeng, Zhang, Yong, Ma, Baozhen, Yang, Yonghao, Shang, Yiman, Fu, Xiaomin, Liang, Guanghui, Yuan, Dongfeng, Qu, Jinrong, Chai, Xiaofei, Zhang, He, Wang, Zibing, Lin, Hongwei, Liu, Liang, Ren, Xiubao, Zhang, Jiangong, Gao, Quanli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685246/ https://www.ncbi.nlm.nih.gov/pubmed/34938292 http://dx.doi.org/10.3389/fimmu.2021.772450 |
Ejemplares similares
-
A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Xing, Wenqun, et al.
Publicado: (2020) -
High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study
por: Zhao, Lingdi, et al.
Publicado: (2022) -
Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer
por: Zhao, Lingdi, et al.
Publicado: (2020) -
Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
por: Ma, Baozhen, et al.
Publicado: (2022) -
Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)